Sobre 1 señal de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Discover the complete record of transactions filed by Epperly Melissa B, Director Financiero. Insider active across 2 companies, notably Zentalis Pharmaceuticals, Inc.. Aggregated, 32 filings have been published. Split: 1 buy · 9 sells. Total volume traded: €1.9m. History available since 3 May 2021. The latest transaction was filed on 17 July 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Epperly Melissa B,
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8094 títulos@ 48,7475 US$0.12% mcap12.7% de su flujoCommon StockSEC:0001725160-22-000069:0
25 de 32 declaraciones
About Epperly Melissa B,
Melissa B. Epperly is Directeur Financier and is linked to Roivant Sciences Ltd. and Zentalis Pharmaceuticals, Inc. Across 31 filings in total, the 31 sampled filings run from 2021-05-05 to 2026-04-21, with 58913 EUR in buys and 1797499 EUR in sells; the most frequent transaction nature is Attribution.